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Abstract 1 
Background Periprosthetic osteolysis resulting in aseptic loosening is a leading cause of THA 2 
revision. Individuals vary in their susceptibility to osteolysis and heritable factors may 3 
contribute to this variation. However, the overall contribution that such variation makes to 4 
osteolysis risk is unknown. 5 
Questions/purposes We conducted two genome-wide association studies to (1) identify 6 
genetic risk loci associated with susceptibility to osteolysis; and (2) identify genetic risk loci 7 
associated with time to prosthesis revision for osteolysis.  8 
Methods The Norway cohort comprised 2624 patients after THA recruited from the 9 
Norwegian Arthroplasty Registry, of whom 779 had undergone revision surgery for 10 
osteolysis. The UK cohort included 890 patients previously recruited from hospitals in the 11 
north of England, 317 who either had radiographic evidence of and/or had undergone revision 12 
surgery for osteolysis. All participants had received a fully cemented or hybrid THA using a 13 
small-diameter metal or ceramic-on-conventional polyethylene bearing. Osteolysis 14 
susceptibility case-control analyses and quantitative trait analyses for time to prosthesis 15 
revision (a proxy measure of the speed of osteolysis onset) in those patients with osteolysis 16 
were undertaken in each cohort separately after genome-wide genotyping. Finally, a meta-17 
analysis of the two independent cohort association analysis results was undertaken.  18 
Results Genome-wide association analysis identified four independent suggestive genetic 19 
signals for osteolysis case-control status in the Norwegian cohort and 11 in the UK cohort (p 20 
 5 x 10-6). After meta-analysis, five independent genetic signals showed a suggestive 21 
association with osteolysis case-control status at p  5 x 10-6 with the strongest comprising 18 22 
correlated variants on chromosome 7 (lead signal rs850092, p = 1.13 x 10-6). Genome-wide 23 
quantitative trait analysis in cases only showed a total of five and nine independent genetic 24 
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signals for time to revision at p  5 x 10-6, respectively. After meta-analysis, 11 independent 25 
genetic signals showed suggestive evidence of an association with time to revision at p  5 x 26 
10-6 with the largest association block comprising 174 correlated variants in chromosome 15 27 
(lead signal rs10507055, p = 1.40 x 10-7).   28 
Conclusions We explored the heritable biology of osteolysis at the whole genome level and 29 
identify several genetic loci that associate with susceptibility to osteolysis or with premature 30 
revision surgery. However, further studies are required to determine a causal association 31 
between the identified signals and osteolysis and their functional role in the disease.  32 
Clinical Relevance The identification of novel genetic risk loci for osteolysis enables new 33 
investigative avenues for clinical biomarker discovery and therapeutic intervention in this 34 
disease.   35 
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Introduction 36 
Despite improvements in modern prosthetic design, 5% to 10% of THA prostheses undergo 37 
revision within 10 years [28, 32]. Although osteolysis after THA has been mitigated by the 38 
use of highly crosslinked polyethylene bearings [22], osteolysis and its sequelae aseptic 39 
loosening remain a leading indication for revision surgery, accounting for 55% of THA 40 
revision procedures worldwide [43]. Revision surgery carries a three- to eightfold greater in-41 
hospital mortality, higher morbidity, and poorer functional outcome versus primary THA [9, 42 
31, 58].  43 
Aseptic loosening is the clinical endpoint of periprosthetic osteolysis, which describes a 44 
progressive resorption of bone caused by a host inflammatory response to particulate wear 45 
debris [15, 25, 44, 45].  This inflammatory bone loss is mediated by proinflammatory 46 
cytokines that upregulate osteoclastogenesis directly or indirectly through receptor activator 47 
RIQXFOHDUIDFWRUț%OLJDQGVLJQDOLQJ [7, 19-21, 24, 52, 56] while also downregulating 48 
osteoblastogenesis [27]. The exact mechanisms involved in this process are still not fully 49 
understood, although several studies have implicated innate immune signaling through 50 
pattern recognition receptor activation by danger and pathogen-associated molecular patterns 51 
[3, 5, 41, 48].  52 
Evidence from in vitro studies suggest that individuals vary in their immunologic response to 53 
wear debris [12, 37]; however, the component of osteolysis that is attributable to heritable 54 
factors remain unclear. Similarly, the genes that modulate the time after surgery when 55 
osteolysis occurs in patients who develop the disease also remain relatively unexplored, and 56 
may differ to those that modulate susceptibility. Several investigators have explored the 57 
relationship between genetic variation within candidate genes and susceptibility to 58 
periprosthetic osteolysis with the first identified association being with the promoter region of 59 
the gene encoding tumor necrosis factor (TNF) [53].  Subsequently, several associations 60 
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between single nucleotide polymorphism (SNPs) in proinflammatory cytokines and bone 61 
turnover pathways and osteolysis have been identified [1, 2, 11, 13, 14, 26, 30, 33-35, 47, 62 
51]. However, our knowledge of the genetics of osteolysis is currently based entirely on 63 
studies using the ³candidate´ gene approach in which the threshold for identifying an 64 
association is low. The only genetic association with osteolysis identified to date that has 65 
been independently replicated is found at the TNF promoter [11, 53].  66 
Candidate gene studies, which are based on a priori hypotheses about the role of a selected 67 
gene or a group of pathway-related genes, have several limitations. These include low sample 68 
sizes leading to low statistical power to detect modest to small effect sizes that are 69 
characteristic of most complex diseases and incomplete coverage of variation across the 70 
genes of interest. Limited knowledge of the etiopathogenesis of disease also restricts the 71 
selection of candidate genes and misses variation in genes lying in previously unsuspected 72 
pathways. In contrast, genome-wide association studies utilize a hypothesis-free approach 73 
enabling the examination of a set of maximally informative markers capturing variation 74 
across the whole genome. This approach has established thousands of reproducible 75 
associations with complex diseases (https://www.ebi.ac.uk/gwas/) [23, 40]. To date, there 76 
have been no systematic studies of the genetic architecture of osteolysis at the whole genome 77 
level. 78 
We conducted two genome-wide association studies and a subsequent meta-analysis to (1) 79 
identify genetic risk loci associated with susceptibility to osteolysis; and (2) identify genetic 80 
risk loci associated with time to prosthesis revision for osteolysis.  81 
Patients and Methods 82 
The Norwegian cohort comprised patients with osteolysis and osteolysis-free matched control 83 
patients after THA. The participants were identified from the Norwegian Arthroplasty 84 
7 
 
 
Register and recruited by postal return of a saliva sample for DNA extraction between April 85 
2009 and December 2011. All patients had previously undergone primary cemented or hybrid 86 
(cemented femur) THA for idiopathic osteoarthritis. The recruitment strategy for the 87 
Norwegian cohort was planned to minimize confounders between the patients with osteolysis 88 
and those in the control group as follows: All live patients recorded in the Norwegian 89 
Arthroplasty Register as having had a revision for the indication of osteolysis or aseptic 90 
loosening (n = 2029) were invited to participate. The revision patients were recruited first and 91 
the control group patients individually matched at a ratio of approximately three to one to be 92 
of the same age (± 2 years), sex, implant fixation method, bearing couple material and head 93 
size (22-mm or 28-mm bearing only), and year of primary surgery (± 2 years). Patients who 94 
had undergone primary THA for an inflammatory arthropathy, femoral neck fracture, 95 
secondary osteoarthritis, or who had a history of infection were excluded. Patients who had 96 
previously undergone revision arthroplasty were also excluded as were those of self-reported 97 
non-European Caucasian ancestry. This exclusion criteria were also confirmed at genotype 98 
screening. In all, 923 patients who had previously undergone revision surgery for osteolysis 99 
responded to the invitation and provided a saliva sample for DNA analysis. A matched group 100 
of  1957 patients identified within the Norwegian Arthroplasty Register as having primary 101 
THA for idiopathic osteoarthritis and with no recorded revision surgery episodes for the 102 
operated hip provided a saliva sample as disease-negative controls. 103 
The 890 patients in the UK cohort had been previously recruited into a research program 104 
examining the genetics of osteolysis, having previously undergone either cemented or hybrid 105 
THA with a metal-on-conventional polyethylene bearing couple for primary osteoarthritis. 106 
The osteolysis group comprised 317 patients with any osteolysis, with or without aseptic 107 
loosening, diagnosed on plain AP and lateral radiographs of the hip using the Harris criteria 108 
[16, 17], and the control group comprised 573 asymptomatic patients at a minimum of 7 109 
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years after primary THA and who had not undergone any revision surgery and were free from 110 
plain radiographic evidence of osteolysis at the time of recruitment. These participants were 111 
identified through hospital records from the north of England and recruited between April 112 
2000 and August 2010 as part of previous ethically approved osteolysis studies [13, 30, 53] 113 
and had DNA archived in South Yorkshire and North Derbyshire Musculoskeletal Biobank.  114 
In both cohorts, patients in the osteolysis group were younger, and a greater proportion were 115 
men when compared with the control group (Table 1). Patients in the control population also 116 
had a longer time since primary THA than the patients with osteolysis, and a greater 117 
proportion in the Norway cohort had fully cemented prostheses and ceramic-on-polyethylene 118 
bearing couples. These findings are consistent with known osteolysis risk factors [15, 18, 49] 119 
and were adjusted for by inclusion as covariates in all subsequent analyses. 120 
DNA Sample Quality Control, Genotyping, and Association Analyses 121 
Genomic DNA from the Norwegian cohort was genotyped on the Infinium Illumina 122 
HumanCoreExome-24 BeadChip Kit (Illumina, San Diego, CA, USA). Genotypes were 123 
called using the Illumina Genome Studio Gencall calling algorithm. All samples underwent 124 
standard quality control (QC) procedures with exclusion criteria as follows: (1) call rate < 125 
80%; (2) gender discrepancy; (3) excess heterozygosity (separately for minor allele frequency 126 
0$) 1% and < 1%); (4) duplicates and/or related; (5) ethnicity outliers; and (6) Fluidigm 127 
concordance (this identity check looks at sample concordance between Illumina and Fluidigm 128 
genotypes). Variants were excluded based on the following: (1) call rate < 98%; (2) Hardy-129 
Weinberg Equilibrium (HWE) p  1 x 10-4; (3) cluster separation score < 0.4; (4) MAF < 130 
0.01; and (5) < four minor allele counts in cases and controls separately. In total, after the 131 
exclusion of samples and variants that failed the QC criteria, 785 osteolysis patients, 1846 132 
control patients, and 508,957 directly typed SNPs remained. Phasing and imputation were 133 
carried out remotely on the Haplotype Reference Consortium (HRC) free servers using 134 
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IMPUTE2 and SHAPEIT3 software (http://www.haplotype-reference-consortium.org/). 135 
Briefly, the HRC reference panel consists of 64,976 human haplotypes at 39,235,157 SNPs 136 
using whole-genome sequence data from 20 studies of predominantly European ancestry 137 
[38]. After imputation and additional QC exclusions (variants with MAF < 0.05, HWE p  138 
10-4, and imputation info VFRUH 0.4), the number of variants reached 5,397,933 and 139 
5,397,567 for case-control status and time-to-revision analyses, respectively. In all, 2631 140 
individuals (779 patients with osteolysis and 1846 patients in the control group) passed the 141 
QC criteria and were used in the case-control analysis, and in the time-to-revision analysis, 142 
only cases were used.   143 
Genomic DNA from patients in the UK cohort was genotyped using the Illumina 610k 144 
beadchip. After QC, the data set was phased and imputed using the HRC reference panel by 145 
applying the same QC metrics used for the Norwegian cohort. After QC, 5,314,896 variants 146 
in 895 individuals proceeded to case-control analysis and 5,415,184 variants in 317 147 
individuals proceeded to time-to-revision analysis.  148 
Association analyses for osteolysis case-control status and time to revision in those patients 149 
with osteolysis were conducted separately for the Norwegian and UK cohorts and made using 150 
the frequentist likelihood ratio test and method ml in SNPTEST v2.5.2 151 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/) [36]. To account for population 152 
stratification, the first 10 principal components were included as covariates in the association 153 
testing. Sex, age at operation, prosthesis fixation method, bearing couple material 154 
combination, and lysis-free survival were also used as covariates in the association analysis. 155 
The same covariates were used for the time-to-prosthesis revision analysis. Because of the 156 
large number of variants tested in genomic studies and the variable levels of linkage 157 
(nonindependence) between the variables, p values of  5 x 10-6 were taken as indicating a 158 
suggestive association between variant and disease status and p  5 x 10-8 as indicating 159 
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genome-wide significance. Power was calculated using Quanto v1.2.4 [38] using p = 5 x 10-8 160 
and fixed the sample size to the size of each cohort separately. 161 
Meta-analysis 162 
We performed a meta-analysis of the two analyzed cohorts using the fixed-effects inverse-163 
variance weighted model implemented in METAL 164 
(http://www.sph.umich.edu/csg/abecasis/metal/) [54]. The total sample size in the combined 165 
cohort consisted of 1096 patients and 2419 control group participants. Variants with per-166 
cohort MAF 0.05, imputation information score > 0.4, and HWE S10-4 were included in 167 
the analysis. To test the heterogeneity of the results, we computed &RFKUDQ¶V4 and the I2 168 
statistic. 169 
Data Availability 170 
Anonymized genotypes of the Norwegian cohort included in this study are publicly available 171 
through the European Genome-Phenome Archive (EGA) under accession number 172 
EGAS00001001883, data set EGAD00010001289. 173 
Results 174 
Genetic Loci Associated With Osteolysis Case-control Status 175 
In the Norwegian cohort, we found a total of 12 SNPs comprising four independent signals 176 
(Manhattan Plot [Fig. 1A], QQ Plot [Fig. 1B]) that were associated with osteolysis case-177 
control status at p  5 x 10-6. A summary of the loci associated with osteolysis is shown 178 
(Supplemental Table 1 [Supplemental materials are available with the online version of 179 
CORR®.]). The variant with the most statistically significant p value was rs8101944, an 180 
upstream variant of PLPP2 (phospholipid phosphatase 2; PPAP2C [phosphatidic acid 181 
phosphatase type 2C]) on chromosome 19 (effect allele [EA] T, effect allele frequency [EAF] 182 
0.06, odds ratio [OR], 0.68; 95% confidence interval [CI], 0.51-0.89; p = 1.26 x 10-6). 183 
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In the UK cohort, we identified a total of 61 SNPs comprising 11 independent signals 184 
(Manhattan Plot [Fig. 2A], QQ Plot [Fig. 2B]) that were associated with osteolysis case-185 
control status at p  5 x 10-6. A summary of the loci associated with osteolysis case-control 186 
status is shown (Supplemental Table 2 [Supplemental materials are available with the online 187 
version of CORR®.]).  The variant with the most statistically significant p value was 188 
rs12135813, an intergenic variant (EA C, EAF 0.37; OR, 0.60; 95% CI, 0.49±0.74; p = 4.34 x 189 
10-7) and lies between the PLXNA2 (plexin A2) and MIR205HG genes on chromosome 1. 190 
Genetic Loci Associated With Time to Prosthesis Revision  191 
In the Norwegian cohort, we identified 32 SNPs comprising five independent signals 192 
(Manhattan Plot [Fig. 3A], QQ Plot [Fig. 3B]) that were associated with time to revision at p 193 
 5 x 10-6. A summary of the loci associated with time to revision is shown (Supplemental 194 
Table 3 [Supplemental materials are available with the online version of CORR®.]). The 195 
variant with the most statistically significant p value is rs282329 (EA T, EAF 0.66; beta ± 196 
standard error [SE] 0.25 ± 0.05; p = 3.06 x 10-7) and lies between the VEZT (vezatin, 197 
adherens junctions transmembrane protein) and METAP2 (methionyl aminopeptidase 2) 198 
protein coding genes on chromosome 12.  199 
Genome-wide analysis in the UK cohort identified 19 signals comprising nine independent 200 
signals (Manhattan Plot [Fig. 4A], QQ Plot [Fig. 4B]) that were associated with time to 201 
revision at p  5 x 10-6. A summary of the loci associated with time-to-revision status is 202 
shown (Supplemental Table 4 [Supplemental materials are available with the online version 203 
of CORR®.]). The variant with the most statistically significant p value was rs184396151 (EA 204 
G, EAF 0.67; beta ± SE 1.34 ± 0.17; p = 6.70 x 10-7) and lies within CUX2 (cut-like 205 
homeobox 2) protein coding gene on chromosome 12. 206 
Genetic Loci Association Meta-analyses  207 
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The results showed that 5,411,522 variants with MAF 0.05 were common to both the 208 
Norwegian and UK osteolysis case-control analyses. After meta-analysis, no signals 209 
approached the genome-wide significance threshold of p  5 x 10-8 (Manhattan Plot [Fig. 210 
5A], QQ Plot [Fig. 5B]). A summary of the loci that associated with osteolysis case-control 211 
status at p  5 x 10-6 is shown (Supplemental Table 5 [Supplemental materials are available 212 
with the online version of CORR®.]). Twenty-nine SNPs, with the same direction of effect in 213 
both cohorts and comprising five independent signals, showed suggestive evidence for an 214 
association with osteolysis susceptibility with p  5 x 10-6. The strongest signal was in 215 
chromosome 7 (Fig. 6) with 18 correlated variants showing p  5 x 10-6. The lead variant 216 
rs850092 (EA A, EAF 0.72; OR, 1.41; 95% CI, 1.23±1.61; p = 1.13 x 10-6), is located within 217 
DPY19L2P3 (DPY19L2 pseudogene 3).  218 
In a meta-analysis across the Norwegian and UK cohorts for time to revision, a total of 219 
5,418,572 variants were analyzed (Manhattan Plot [Fig. 7A], QQ Plot [Fig. 7B]). A summary 220 
of the loci that were associated with time to revision at p  5 x 10-6 is shown (Supplemental 221 
Table 6 [Supplemental materials are available with the online version of CORR®.]). In all, 222 
209 variants with the same direction of effect in both cohorts and comprising 11 independent 223 
signals showed suggestive evidence for association with time-to-prosthesis revision with p  224 
5 x 10-6. rs10507055 (Fig. 8) had the most statistically significant p value (EA T, EAF 0.37; 225 
beta ± SE -0.22 ± 0.04; p = 1.40 x 10-7) and is in the same region of chromosome 12 as 226 
rs282329, which had the most statistically significant p value in the Norwegian cohort 227 
association analysis. A block of 174 correlated variants with p  5 x 10-6 was found in 228 
chromosome 15 (Fig. 9). rs12899987 is the lead variant and lies within the gene OTUD7A 229 
(EA T, EAF 0.81; beta ± SE 0.26 ± 0.05; p = 2.80 x 10-7).  230 
Discussion 231 
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Although osteolysis after THA has been mitigated substantially by the use of highly 232 
crosslinked polyethylene bearings, osteolysis and its sequelae aseptic loosening remain a 233 
leading indication for revision surgery. Previous studies have observed that interindividual 234 
differences in susceptibility to osteolysis may have a genetic basis [1, 2, 34, 53], but this 235 
question has not been examined systematically at the genome-wide level. In this study, in two 236 
European cohorts, we explored the contribution that variation across the human genome 237 
makes to osteolysis and found evidence of a modest heritable contribution to disease 238 
susceptibility. We found replicating evidence for suggestive association of several genetic 239 
loci with susceptibility to osteolysis and with time to revision in those patients with 240 
osteolysis. The largest association block in the case-control meta-analysis centered on the 241 
gene encoding DPY19L2 pseudogene 3 on the short arm of chromosome 7 (intronic variant 242 
rs850092). This gene has not been characterized previously and its function is unknown. 243 
However, this signal also lies adjacent to microRNA 550a-3 (MiR550A3). MicroRNAs are a 244 
recently discovered group of RNAs that function to regulate the production of other peptides 245 
and are currently being explored as putative biomarkers and treatments for musculoskeletal 246 
and other diseases [4, 6, 39, 42]. In our quantitative trait meta-analysis of time-to-prosthesis 247 
revision, we identified a large block of 174 correlated variants in chromosome 15. The lead 248 
signal for this block was intronic variant rs12899987 that lies within the gene encoding OTU 249 
deubiquitinase 7A (OTUD7A). OTUD7A is an intracellular enzyme that modulates NFʃB 250 
signaling through TRAF6 that is pivotal in proinflammatory cytokine signaling in 251 
periprosthetic osteolysis [55] and represents a potentially actionable target in its prevention 252 
[29]. The most statistically significant signal in the time-to-revision analysis lies within the 253 
gene LOC105369917. The function of this gene has not been explored. However, this signal 254 
also lies adjacent to two further microRNA sites, MiR331 and MiR3685. Further exploration 255 
by fine mapping of these loci is required to identify the causal variants at each signal. 256 
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This study has several limitations. Although these cohorts represent a nationwide and a large 257 
regional cohort purposely collected for the study of osteolysis genetics, the sample sizes 258 
remain small compared with other population-based genomic studies [10, 50, 57]. For the 259 
case-control analysis, we had > 80% power to detect ORs of 1.5 to 1.9 for variants with MAF 260 
5% to 15% using the combined sample size and combined case/control ratio (1:2.2).  For the 261 
continuous trait, we assumed a population mean of 0 and a SD of 1. The combined sample 262 
size had > 80% power to detect variants at genome-wide significance (p < 5 x 10-8) with 263 
modest effect size (beta of 1.3 to 1.5) for common variants (MAF, 0.5 to 0.15) and moderate 264 
effect size (beta of 1.6 to 2.0) for variants with MAF 0.14 to 0.05. However, similar sample 265 
sizes have been used previously to identify the genetic underpinnings in other complex 266 
musculoskeletal diseases, including the association of Wnt signaOLQJZLWK'XSX\WUHQ¶V267 
disease (n = 960 cases) [8]. 268 
The case-ascertainment approach also differed between the cohorts. The UK participants 269 
were recruited face to face using the primary hospital record and included radiographic 270 
evidence of osteolysis or the revision operative record, as described previously, and 271 
comprised all patients who fit the relevant inclusion and exclusion criteria. The known 272 
epidemiologic risk factors for osteolysis were therefore also reflected in the UK study 273 
population. Although this provides evidence for the generalizability of our findings to other 274 
populations, we had to adjust for these covariates in the genetic association analyses. All 275 
analyses are shown postadjustment for these clinical risk factors as well as for unidentified 276 
population and analytical stratification using principal component and regression analysis. 277 
The Norwegian cohort study design and recruitment were made using the Norwegian 278 
Arthroplasty Register as the source data set with documented revision events and indications 279 
recorded by the operating surgeon.  The patients with osteolysis were recruited before the 280 
control patients and at a control:case ratio of 3:1 with screening to match the demographic 281 
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characteristics and implant type and operation year (± 2 years) as closely as possible. This 282 
approach allowed the recruitment of a large case-control matched population but increases 283 
the risk of ascertainment bias because patients with silent osteolysis may have been recorded 284 
as controls and cases could have been misdiagnosed.  Despite this approach, small statistical 285 
differences in population demographics remained because of the large sample sizes involved, 286 
although their clinical relevance may be limited. For example, the mean age at primary 287 
operation in the Norwegian control patients was 66 years, whereas it was 64 years in the 288 
patients with osteolysis. We adjusted for these residual differences in the Norwegian cohort 289 
association analysis in the same manner as we did for the UK cohort. 290 
We found more genetic signals within the UK versus the Norwegian population despite the 291 
smaller cohort size. These differences may be genuine. The observed differences might also 292 
reflect differences in case ascertainment or other unknown biases between the cohorts. 293 
However, the population-level genomic architecture of both cohorts by variant allele 294 
frequency was similar, indicating no significant genetic heterogeneity between the cohorts. 295 
The study participants in each cohort also came from different healthcare economies with 296 
potential differences in diagnostic and treatment thresholds. Individual surgeons¶FOLQLFDO297 
practices also differ, resulting in management variation both between and within the cohorts. 298 
However, these types of classification differences are unlikely to map to particular genotypes, 299 
and thus their likely effect is to create noise limiting the ability of the study to detect genuine 300 
genetic signals rather than increasing the false-positive discovery rate. 301 
We, and others, have previously shown the association of osteolysis with variation in several 302 
candidate genes [11, 30]. In these studies, the genes are selected based on their known 303 
biologic function or previous association of the selected variants with other diseases that 304 
share biologic similarities. The threshold for statistical significance is also set low (typically 305 
at p < 0.05), favoring the identification of a positive association. Although these discovery 306 
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studies lend support to the concept of a disease driven by heritable variation, these 307 
associations commonly are not reproduced when examined in independent cohorts [46], and 308 
the overall contribution of genetic variation to the disease remains unanswered. In contrast, 309 
genome-wide studies allow examination of the overall genetic architecture of the disease that 310 
underpins the differences in susceptibility between individuals. However, these studies 311 
require larger sample sizes and are accompanied by substantially more stringent thresholds 312 
for significance. 313 
The data presented here suggest the association of several previously unstudied genomic loci 314 
with osteolysis. The observations that such loci may reside within areas of the genome about 315 
which we still know very little provide the opportunity for novel avenues for exploration of 316 
the disease. However, further replication of the observed associations is required to confirm 317 
their validity, fine-mapping to precisely localize causal associations, and experimental study 318 
of their biologic function will enable us to clearly understand their role in osteolysis biology 319 
and to translate this new knowledge into diagnostic and therapeutic tools.  320 
 321 
  322 
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Legends 
Figure 1A-B. (A) Manhattan plot of the Norwegian cohort case-control status analysis 
showing the -log10 p values for each variant (y axis) plotted against their respective 
chromosomal position (x axis) and illustrating four independent genetic association peaks in 
785 patients with osteolysis versus 1846 osteolysis-free patients. (B) Graph showing QQ plot 
of the p values for the Norwegian cohort case-control status, where the x-axis indicates the 
H[SHFWHGíORJSYDOXHVDQGWKH\-axis the observed ones. The red line represents the null 
hypothesis of no association at any locus and Ȝ is the genomic inflation factor. 
Figure 2A-B. (A) Manhattan plot of the UK cohort case-control status analysis showing the -
log10 p values for each variant (y axis) plotted against their respective chromosomal position 
(x axis) and illustrating 11 independent genetic association peaks in 317 patients with 
osteolysis versus 517 osteolysis-free patients. (B) Graph showing QQ plot of the p values for 
the UK cohort case-control status association analysis, where the x-axis indicates the 
H[SHFWHGíORJSYDOXHVDQGWKH\-axis the observed ones. The red line represents the null 
hypothesis of no association at any locus and Ȝ is the genomic inflation factor. 
Figure 3A-B. (A) Manhattan plot of the Norwegian cohort time to revision association 
analysis in osteolysis patients only (n = 785) showing the -log10 p values for each variant (y-
axis) plotted against their respective chromosomal position (x-axis) and illustrating five 
independent genetic association peaks. (B) Graph showing QQ plot of the p values for the 
Norwegian cohort time to revision association analysis, where the x-axis indicates the 
H[SHFWHGíORJSYDOXHVDQGWKH\-axis the observed ones. The red line represents the null 
hypothesis of no association at any locus and Ȝ is the genomic inflation factor. 
Figure 4A-B. (A) Manhattan plot of the UK cohort time to revision association analysis in 
osteolysis patients only (n = 317) showing the -log10 p values for each variant (y axis) 
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plotted against their respective chromosomal position (x axis) and illustrating nine 
independent genetic association peaks. (B) Graph showing QQ plot of the p values for the 
UK cohort time to revision association analysis, where the x-axis indicates the expected 
ílog10 p values and the y-axis the observed ones. The red line represents the null hypothesis 
of no association at any locus and Ȝ is the genomic inflation factor. 
Figure 5A-B. (A) Manhattan plot of the Norwegian and UK cohort case-control status meta-
analysis showing the -log10 p values for each variant (y-axis) plotted against their respective 
chromosomal position (x-axis) and illustrating five independent genetic association peaks in 
1096 patients with osteolysis versus 2419 osteolysis-free patients. (B) Graph showing QQ 
plot of the p values for the Norwegian and UK cohort case-control status meta-analysis, 
where the x-axis indicates the exSHFWHGíORJSYDOXHVDQGWKH\-axis the observed ones. 
The red line represents the null hypothesis of no association at any locus and Ȝ is the genomic 
inflation factor. 
Figure 6. Regional association plot showing the lead osteolysis susceptibility signal at 
rs850092 in the case-control association meta-analysis. Each filled circle represents the p 
value of analyzed variants (as -log10 p values) plotted against their physical position (NCBI 
Build 37). The p value at the index variant is represented by a purple circle. The other 
variants in the region are colored depending on their degree of correlation (r2) with the index 
variant according to a scale from r2 = 0 (blue) to r2 = 1 (red). Gene location is annotated based 
on the UCSC genome browser. 
Figure 7A-B. (A) Manhattan plot of the Norwegian and UK cohort time-to-revision 
association meta-analysis in osteolysis patients only (n = 1096) showing the -log10 p values 
for each variant (y-axis) plotted against their respective chromosomal position (x-axis) and 
illustrating 11 independent genetic association peaks. (B) Graph showing QQ plot of the p 
values for the Norwegian cohort time-to-revision association analysis, where the x-axis 
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LQGLFDWHVWKHH[SHFWHGíORJSYDlues and the y-axis the observed ones. The red line 
represents the null hypothesis of no association at any locus and Ȝ is the genomic inflation 
factor. 
Figure 8. Regional association plot showing the lead time to prosthesis revision signal at 
rs10507055 in the association meta-analysis. Each filled circle represents the p value of 
analyzed variants (as -log10 p values) plotted against their physical position (NCBI Build 37). 
The p value at the index variant is represented by a purple circle. The other variants in the 
region are colored depending on their degree of correlation (r2) with the index variant 
according to a scale from r2 = 0 (blue) to r2 = 1 (red). Gene location is annotated based on the 
UCSC genome browser. 
Figure 9. Regional association plot showing the lead time to revision signal at rs12899987 in 
the association meta-analysis. Each filled circle represents the p value of analyzed variants 
(as -log10 p values) plotted against their physical position (NCBI Build 37). The p value at the 
index variant is represented by a purple circle. The other variants in the region are colored 
depending on their degree of correlation (r2) with the index variant according to a scale from 
r2 = 0 (blue) to r2 = 1 (red). Gene location is annotated based on the UCSC genome browser. 
